Analysis of human genetic factors determining anti-HBV immune response to HBV reactivation or HB vaccine after allogeneic hematopoietic cell transplantatio

Not Applicable

Recruiting

• Conditions: hematological malignancies

• Registration Number: JPRN-UMIN000053399
• Lead Sponsor: Japan Agency for Medical Research and Development

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-20
• Last Update Posted: 23 April 2024
• Study Completion: 2024-12-01

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analysis of immunological response against post-transplant HBV reactivation and HB vaccine by donor cell genetic factors. Determine whether immune response against HBV reactivation after allogeneic hematopoietic cell transplantation and HB vaccine are affected by HLA type, BTNL2 genetic polymorphism, etc.